Celon Pharma Past Earnings Performance
Past criteria checks 0/6
Celon Pharma's earnings have been declining at an average annual rate of -73.1%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been growing at an average rate of 14.1% per year.
Key information
-73.1%
Earnings growth rate
-73.1%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | 14.1% |
Return on equity | -6.3% |
Net Margin | -13.1% |
Next Earnings Update | 22 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Celon Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 214 | -28 | 111 | 0 |
30 Sep 23 | 214 | -25 | 108 | 0 |
30 Jun 23 | 211 | -30 | 108 | 0 |
31 Mar 23 | 196 | -47 | 111 | 0 |
31 Dec 22 | 194 | -39 | 108 | 0 |
30 Sep 22 | 191 | -31 | 108 | 0 |
30 Jun 22 | 186 | -28 | 100 | 0 |
31 Mar 22 | 191 | -17 | 96 | 0 |
31 Dec 21 | 196 | -12 | 90 | 0 |
30 Sep 21 | 186 | -11 | 89 | 0 |
30 Jun 21 | 185 | -2 | 86 | 0 |
31 Mar 21 | 170 | 0 | 91 | -10 |
31 Dec 20 | 157 | -1 | 83 | 0 |
30 Sep 20 | 142 | 4 | 72 | 0 |
30 Jun 20 | 128 | 5 | 70 | 0 |
31 Mar 20 | 109 | 3 | 63 | 10 |
31 Dec 19 | 102 | 12 | 62 | 0 |
30 Sep 19 | 110 | 17 | 60 | 0 |
30 Jun 19 | 118 | 23 | 38 | 0 |
31 Mar 19 | 124 | 29 | 40 | 0 |
31 Dec 18 | 125 | 30 | 37 | 0 |
30 Sep 18 | 116 | 30 | 33 | 0 |
30 Jun 18 | 109 | 26 | 47 | 0 |
31 Mar 18 | 107 | 28 | 35 | 0 |
31 Dec 17 | 107 | 26 | 35 | 0 |
30 Sep 17 | 129 | 22 | 41 | 0 |
30 Jun 17 | 127 | 24 | 41 | 0 |
31 Mar 17 | 115 | 27 | 31 | 0 |
31 Dec 16 | 129 | 38 | 34 | 0 |
30 Sep 16 | 111 | 42 | 55 | 0 |
31 Dec 15 | 108 | 37 | 55 | 0 |
31 Dec 14 | 98 | 52 | 51 | 0 |
31 Dec 13 | 72 | 18 | 39 | 0 |
Quality Earnings: 8RP is currently unprofitable.
Growing Profit Margin: 8RP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 8RP is unprofitable, and losses have increased over the past 5 years at a rate of 73.1% per year.
Accelerating Growth: Unable to compare 8RP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 8RP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.6%).
Return on Equity
High ROE: 8RP has a negative Return on Equity (-6.31%), as it is currently unprofitable.